1
|
Patrigeon M, Brot S, Bonnet ML, Belnoue L, Gaillard A. Host-to-graft Propagation of α-synuclein in a Mouse Model of Parkinson's Disease: Intranigral Versus Intrastriatal Transplantation. Transplantation 2023; 107:e201-e212. [PMID: 36944598 DOI: 10.1097/tp.0000000000004565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
BACKGROUND Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) and by the accumulation of misfolded α-synuclein (α-syn) in Lewy bodies. Ectopic transplantation of human fetal ventral mesencephalic DA neurons into the striatum of PD patients have provided proof-of-principle for the cell replacement strategy in this disorder. However, 10 to 22 y after transplantation, 1% to 27% of grafted neurons contained α-syn aggregates similar to those observed in the host brain. We hypothesized that intrastriatal grafts are more vulnerable to α-syn propagation because the striatum is not the ontogenic site of nigral DA neurons and represents an unfavorable environment for transplanted neurons. Here, we compared the long-term host-to-graft propagation of α-syn in 2 transplantation sites: the SNpc and the striatum. METHODS Two mouse models of PD were developed by injecting adeno-associated-virus2/9-human α-syn A53T into either the SNpc or the striatum of C57BL/6 mice. Mouse fetal ventral mesencephalic DA progenitors were grafted into the SNpc or into the striatum of SNpc or striatum of α-syn injected mice, respectively. RESULTS First, we have shown a degeneration of the nigrostriatal pathway associated with motor deficits after nigral but not striatal adeno-associated-virus-hαsyn A53T injection. Second, human α-syn preferentially accumulates in striatal grafts compared to nigral grafts. However, no differences were observed for phosphorylated α-syn, a marker of pathological α-syn aggregates. CONCLUSIONS Taken together, our results suggest that the ectopic site of the transplantation impacts the host-to-graft transmission of α-syn.
Collapse
Affiliation(s)
- Maëlig Patrigeon
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers Cedex, France
| | - Sébastien Brot
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers Cedex, France
| | - Marie-Laure Bonnet
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers Cedex, France
- CHU Poitiers, Poitiers, France
| | - Laure Belnoue
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers Cedex, France
- CHU Poitiers, Poitiers, France
| | - Afsaneh Gaillard
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers Cedex, France
| |
Collapse
|
2
|
Brot S, Thamrin NP, Bonnet ML, Francheteau M, Patrigeon M, Belnoue L, Gaillard A. Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson's Disease Mouse Model. Cells 2022; 11:cells11101596. [PMID: 35626637 PMCID: PMC9140181 DOI: 10.3390/cells11101596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/04/2022] [Accepted: 05/05/2022] [Indexed: 11/16/2022] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). One strategy for treating PD is transplantation of DA neuroblasts. Significant advances have been made in generating midbrain DA neurons from human pluripotent stem cells. Before these cells can be routinely used in clinical trials, extensive preclinical safety studies are required. One of the main issues to be addressed is the long-term therapeutic effectiveness of these cells. In most transplantation studies using human cells, the maturation of DA neurons has been analyzed over a relatively short period not exceeding 6 months. In present study, we generated midbrain DA neurons from human induced pluripotent stem cells (hiPSCs) and grafted these neurons into the SNpc in an animal model of PD. Graft survival and maturation were analyzed from 1 to 12 months post-transplantation (mpt). We observed long-term survival and functionality of the grafted neurons. However, at 12 mpt, we observed a decrease in the proportion of SNpc DA neuron subtype compared with that at 6 mpt. In addition, at 12 mpt, grafts still contained immature neurons. Our results suggest that longer-term evaluation of the maturation of neurons derived from human stem cells is mandatory for the safe application of cell therapy for PD.
Collapse
Affiliation(s)
- Sébastien Brot
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
| | - Nabila Pyrenina Thamrin
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
| | - Marie-Laure Bonnet
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
- CHU Poitiers, 86022 Poitiers, France
| | - Maureen Francheteau
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
| | - Maëlig Patrigeon
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
| | - Laure Belnoue
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
- CHU Poitiers, 86022 Poitiers, France
| | - Afsaneh Gaillard
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM 1084, 86022 Poitiers, France; (S.B.); (N.P.T.); (M.-L.B.); (M.F.); (M.P.); (L.B.)
- Correspondence: ; Tel.: +33-54-945-3873
| |
Collapse
|
3
|
Ballout N, Rochelle T, Brot S, Bonnet ML, Francheteau M, Prestoz L, Zibara K, Gaillard A. Characterization of Inflammation in Delayed Cortical Transplantation. Front Mol Neurosci 2019; 12:160. [PMID: 31293384 PMCID: PMC6603085 DOI: 10.3389/fnmol.2019.00160] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 06/07/2019] [Indexed: 01/30/2023] Open
Abstract
We previously reported that embryonic motor cortical neurons transplanted 1-week after lesion in the adult mouse motor cortex significantly enhances graft vascularization, survival, and proliferation of grafted cells, the density of projections developed by grafted neurons and improves functional repair and recovery. The purpose of the present study is to understand the extent to which post-traumatic inflammation following cortical lesion could influence the survival of grafted neurons and the development of their projections to target brain regions and conversely how transplanted cells can modulate host inflammation. For this, embryonic motor cortical tissue was grafted either immediately or with a 1-week delay into the lesioned motor cortex of adult mice. Immunohistochemistry (IHC) analysis was performed to determine the density and cell morphology of resident and peripheral infiltrating immune cells. Then, in situ hybridization (ISH) was performed to analyze the distribution and temporal mRNA expression pattern of pro-inflammatory or anti-inflammatory cytokines following cortical lesion. In parallel, we analyzed the protein expression of both M1- and M2-associated markers to study the M1/M2 balance switch. We have shown that 1-week after the lesion, the number of astrocytes, microglia, oligodendrocytes, and CD45+ cells were significantly increased along with characteristics of M2 microglia phenotype. Interestingly, the majority of microglia co-expressed transforming growth factor-β1 (TGF-β1), an anti-inflammatory cytokine, supporting the hypothesis that microglial activation is also neuroprotective. Our results suggest that the modulation of post-traumatic inflammation 1-week after cortical lesion might be implicated in the improvement of graft vascularization, survival, and density of projections developed by grafted neurons.
Collapse
Affiliation(s)
- Nissrine Ballout
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France.,Laboratory of Stem Cells, PRASE, DSST, Department of Biology, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon
| | - Tristan Rochelle
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France
| | - Sebastien Brot
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France
| | - Marie-Laure Bonnet
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France.,CHU Poitiers, Poitiers, France
| | - Maureen Francheteau
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France
| | - Laetitia Prestoz
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France
| | - Kazem Zibara
- Laboratory of Stem Cells, PRASE, DSST, Department of Biology, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon
| | - Afsaneh Gaillard
- Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM U1084, Poitiers, France
| |
Collapse
|
4
|
Sandt C, Feraud O, Bonnet ML, Desterke C, Khedhir R, Flamant S, Bailey CG, Rasko JEJ, Dumas P, Bennaceur-Griscelli A, Turhan AG. Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. Biochem Biophys Res Commun 2018; 503:1861-1867. [PMID: 30057314 DOI: 10.1016/j.bbrc.2018.07.127] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 07/20/2018] [Accepted: 07/24/2018] [Indexed: 01/07/2023]
Abstract
Despite the major success obtained by the use of tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML), resistances to therapies occur due to mutations in the ABL-kinase domain of the BCR-ABL oncogene. Amongst these mutations, the "gatekeeper" T315I is a major concern as it renders leukemic cells resistant to all licenced TKI except Ponatinib. We report here that Fourier transform infrared (FTIR) microspectroscopy is a powerful methodology allowing rapid and direct identification of a spectral signature in single cells expressing T315I-mutated BCR-ABL. The specificity of this spectral signature is confirmed using a Dox-inducible T315I-mutated BCR-ABL-expressing human UT-7 cells as well as in murine embryonic stem cells. Transcriptome analysis of UT-7 cells expressing BCR-ABL as compared to BCR-ABL T315I clearly identified a molecular signature which could be at the origin of the generation of metabolic changes giving rise to the spectral signature. Thus, these results suggest that this new methodology can be applied to the identification of leukemic cells harbouring the T315I mutation at the single cell level and could represent a novel early detection tool of mutant clones. It could also be applied to drug screening strategies to target T315I-mutated leukemic cells.
Collapse
MESH Headings
- Animals
- Cell Line
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Mice
- Mutation
- Spectroscopy, Fourier Transform Infrared
Collapse
Affiliation(s)
| | | | | | | | | | | | - Charles G Bailey
- Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Locked Bag No 6, Newtown, NSW, 2042, Australia; Sydney Medical School, University of Sydney, 2006, NSW, Australia
| | - John E J Rasko
- Gene and Stem Cell Therapy Program, Centenary Institute, University of Sydney, Locked Bag No 6, Newtown, NSW, 2042, Australia; Sydney Medical School, University of Sydney, 2006, NSW, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, 2052, NSW, Australia
| | - Paul Dumas
- SOLEIL Synchrotron, Saint Aubin, 91192, Gif sur Yvette, France
| | - Annelise Bennaceur-Griscelli
- INSERM UMR_S_935, Campus CNRS, Villejuif, France; Department of Hematology, Paris Sud Hematology Institute, AP-HP Hôpital Paul Brousse, Villejuif, France; INGESTEM National Pluripotent Stem Cell Infrastructure, University Paris Sud 11, Villejuif, France
| | - Ali G Turhan
- INSERM UMR_S_935, Campus CNRS, Villejuif, France; Department of Hematology, Paris Sud Hematology Institute, AP-HP Hôpital Paul Brousse, Villejuif, France; INGESTEM National Pluripotent Stem Cell Infrastructure, University Paris Sud 11, Villejuif, France.
| |
Collapse
|
5
|
Desterke C, Voldoire M, Bonnet ML, Sorel N, Pagliaro S, Rahban H, Bennaceur-Griscelli A, Cayssials E, Chomel JC, Turhan AG. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). Exp Hematol 2018; 64:71-83.e8. [DOI: 10.1016/j.exphem.2018.04.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 04/25/2018] [Accepted: 04/27/2018] [Indexed: 01/13/2023]
|
6
|
Chomel JC, Bonnet ML, Sorel N, Sloma I, Bennaceur-Griscelli A, Rea D, Legros L, Marfaing-Koka A, Bourhis JH, Ame S, Guerci-Bresler A, Rousselot P, Turhan AG. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 2018; 7:35293-301. [PMID: 27167108 PMCID: PMC5085229 DOI: 10.18632/oncotarget.9182] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 04/10/2016] [Indexed: 11/25/2022] Open
Abstract
During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has been demonstrated that BCR-ABL1- expressing leukemic stem cells (LSCs) persist in patients in deep molecular response. It has also been shown that the discontinuation of Imatinib leads to a molecular relapse in the majority of cases. To determine a possible relationship between these two phenomena, we have evaluated by clonogenic and long-term culture initiating cell (LTC-IC) assays, the presence of BCR-ABL1-expressing LSCs in marrow samples from 21 patients in deep molecular response for three years after TKI therapy (mean duration seven years). LSCs were detected in 4/21 patients. Discontinuation of TKI therapy in 13/21 patients led to a rapid molecular relapse in five patients (4 without detectable LSCs and one with detectable LSCs). No relapse occurred in the eight patients still on TKI therapy, whether LSCs were detectable or not. Thus, this study demonstrates for the first time the in vivo efficiency of TKIs, both in the progenitor and the LSC compartments. It also confirms the persistence of leukemic stem cells in patients in deep molecular response, certainly at the origin of relapses. Finally, it emphasizes the difficulty of detecting residual LSCs due to their rarity and their low BCR-ABL1 mRNA expression.
Collapse
Affiliation(s)
- Jean Claude Chomel
- Laboratoire de Cancérologie Biologique, CHU de Poitiers, Poitiers, France.,INSERM U935, Poitiers, France
| | | | - Nathalie Sorel
- Laboratoire de Cancérologie Biologique, CHU de Poitiers, Poitiers, France.,INSERM U935, Poitiers, France
| | - Ivan Sloma
- Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France
| | - Annelise Bennaceur-Griscelli
- Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France
| | - Delphine Rea
- Service d'Hématologie Adulte, Hôpital Saint Louis, Paris, France.,INSERM UMRS-1160, IUH-Université Paris Diderot-Paris 7, Paris, France
| | - Laurence Legros
- Service d'Hématologie Clinique, Hôpital l'Archet, Nice, France
| | - Anne Marfaing-Koka
- Service d'Hématologie Biologique, Hôpital Antoine Béclère, Clamart, France
| | - Jean-Henri Bourhis
- Service d'Hématologie Biologique, Hôpital Antoine Béclère, Clamart, France.,Service d'Hématologie-Greffe de Moelle, Institut Gustave Roussy, Villejuif, France
| | - Shanti Ame
- Département d'Hématologie et Oncologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | - Philippe Rousselot
- Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Versailles, France.,EA4340, Université Versailles-Saint Quentin en Yvelines, Université Paris-Saclay, France
| | - Ali G Turhan
- INSERM U935, Poitiers, France.,Service d'Hématologie Biologique, Hôpital Paul Brousse, Villejuif, France.,INSERM U935, Villejuif, France.,Université Paris Sud, Le Kremlin-Bicêtre, France.,Service d'Hématologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
7
|
Chiter F, Bonnet ML, Lacaze-Dufaure C, Tang H, Pébère N. Corrosion protection of Al(111) by 8-hydroxyquinoline: a comprehensive DFT study. Phys Chem Chem Phys 2018; 20:21474-21486. [DOI: 10.1039/c8cp03312a] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The corrosion protective 8HQ monolayer on Al(111).
Collapse
Affiliation(s)
- Fatah Chiter
- CIRIMAT, Université de Toulouse
- CNRS
- INPT-ENSIACET 4
- 31030 Toulouse Cedex 4
- France
| | - Marie-Laure Bonnet
- CIRIMAT, Université de Toulouse
- CNRS
- INPT-ENSIACET 4
- 31030 Toulouse Cedex 4
- France
| | | | - Hao Tang
- CEMES
- UPR CNRS 8011
- 31055 Toulouse Cedex 4
- France
| | - Nadine Pébère
- CIRIMAT, Université de Toulouse
- CNRS
- INPT-ENSIACET 4
- 31030 Toulouse Cedex 4
- France
| |
Collapse
|
8
|
Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leuk Res 2017; 60:94-102. [PMID: 28772207 DOI: 10.1016/j.leukres.2017.07.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 07/01/2017] [Accepted: 07/25/2017] [Indexed: 01/05/2023]
Abstract
Although it has been well-demonstrated that bone marrow mesenchymal stromal cells (MSCs) from CML patients do not belong to the Ph1-positive clone, there is growing evidence that they could play a role in the leukemogenesis process or the protection of leukemic stem cells from the effects of tyrosine kinase inhibitors (TKIs). The aim of the present study was to identify genes differentially expressed in MSCs isolated from CML patients at diagnosis (CML-MSCs) as compared to MSCs from healthy controls. Using a custom gene-profiling assay, we identified six genes over-expressed in CML-MSCs (BMP1, FOXO3, MET, MITF, NANOG, PDPN), with the two highest levels being documented for PDPN (PODOPLANIN) and NANOG. To determine whether this aberrant signature persisted in patients in deep molecular response induced by TKIs, we analyzed MSCs derived from such patients (MR-MSCs). This analysis showed that, despite the deep molecular responses, BMP1, MET, MITF, NANOG, and PDPN mRNA were upregulated in MR-MSCs. Moreover, BMP1, MITF, and NANOG mRNA expressions in MR-MSCs were found to be intermediate between control MSCs and CML-MSCs. These results suggest that CML-MSCs exhibit an abnormal gene expression pattern which might have been established during the leukemogenic process and persist in patients in deep molecular response.
Collapse
Affiliation(s)
| | - Nathalie Sorel
- INSERM, U935, F-86000 Poitiers, France; CHU de Poitiers, Service de Cancérologie Biologique, F-86021 Poitiers, France
| | | | - Jean-Michel Goujon
- CHU de Poitiers, Service d'Anatomie et cytologie pathologiques, F-86021 Poitiers, France; INSERM, U1082, F-86021 Poitiers, France
| | | | - Olivier Hérault
- CHU de Tours, Service d'Hématologie Biologique, F-37032 Tours, France; CNRS UMR 7292, équipe LNOx, Université François Rabelais, F-37032 Tours, France
| | - Jorge Domenech
- CHU de Tours, Service d'Hématologie Biologique, F-37032 Tours, France; CNRS UMR 7292, équipe LNOx, Université François Rabelais, F-37032 Tours, France
| | - Delphine Réa
- Hôpital Saint Louis, Service d'Hématologie Adulte, F-75000 Paris, France; INSERM, UMRS-1160, IUH-Université Paris Diderot-Paris 7, F-75000 Paris, France
| | - Laurence Legros
- Hôpital l'Archet, Service d'Hématologie Clinique, F-06202 Nice, France
| | | | - Philippe Rousselot
- Centre Hospitalier de Versailles, Service d'Hématologie et Oncologie, F-78150 Le Chesnay, France; EA4340, Université Versailles-Saint Quentin en Yvelines, Université Paris-Saclay, France
| | - Emilie Cayssials
- INSERM, CIC-P 0802, F-86000 Poitiers, France; CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, F-86000, Poitiers, France
| | | | - Annelise Bennaceur-Griscelli
- Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France
| | - Jean-Claude Chomel
- INSERM, U935, F-86000 Poitiers, France; CHU de Poitiers, Service de Cancérologie Biologique, F-86021 Poitiers, France
| | - Ali G Turhan
- INSERM, U935, F-86000 Poitiers, France; Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France; NSERM U935, F-94807 Villejuif, France; Université Paris Sud, F-94270 Le Kremlin-Bicêtre, France; Hôpital Bicêtre, Service d'Hématologie Biologique, F-94270 Le Kremlin Bicêtre, France.
| |
Collapse
|
9
|
Levescot A, Flamant S, Basbous S, Jacomet F, Féraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, Chomel JC, Turhan A, Guilhot F, Girard JP, Gombert JM, Herbelin A. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74:2669-76. [PMID: 24675360 DOI: 10.1158/0008-5472.can-13-2797] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Although it is generally acknowledged that cytokines regulate normal hematopoiesis in an autocrine/paracrine fashion, their possible role in chronic myelogenous leukemia (CML) and resistance to imatinib mesylate treatment remain poorly investigated. Here, we report that CD34(+) progenitors from patients with CML at diagnosis are selectively targeted by the cytokine/alarmin interleukin (IL)-33. Indeed, CML CD34(+) progenitors upregulate their cell surface expression of the IL-33-specific receptor chain ST2, proliferate and produce cytokines in response to IL-33, conversely to CD34(+) cells from healthy individuals. Moreover, ST2 overexpression is normalized following imatinib mesylate therapy, whereas IL-33 counteracts in vitro imatinib mesylate-induced growth arrest in CML CD34(+) progenitors via reactivation of the STAT5 pathway, thus supporting the notion that IL-33 may impede the antiproliferative effects of imatinib mesylate on CD34(+) progenitors in CML. Clinically, the levels of circulating soluble ST2, commonly considered a functional signature of IL-33 signaling in vivo, correlate with disease burden. Indeed, these elevated peripheral concentrations associated with a high Sokal score predictive of therapeutic outcome are normalized in patients in molecular remission. Finally, we evidenced a facilitating effect of IL-33 on in vivo maintenance of CD34(+) progenitors from patients with CML by using xenotransplant experiments in immunodeficient NOG mice, and we showed that engraftment of mouse BCR-ABL-transfected bone marrow progenitors was less efficient in IL-33-deficient mice compared with wild-type recipients. Taken together, our results provide evidence that IL-33/ST2 signaling may represent a novel cytokine-mediated mechanism contributing to CML progenitor growth and support a role for this pathway in CML maintenance and imatinib mesylate resistance.
Collapse
Affiliation(s)
- Anaïs Levescot
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Stéphane Flamant
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Sara Basbous
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Florence Jacomet
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - Olivier Féraud
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Elvire Anne Bourgeois
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Marie-Laure Bonnet
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Christine Giraud
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - Lydia Roy
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - Anne Barra
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - Jean-Claude Chomel
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Ali Turhan
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - François Guilhot
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - Jean-Philippe Girard
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, France
| | - Jean-Marc Gombert
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| | - André Herbelin
- Authors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d'Hématologie et d'Oncologie Biologique, Poitiers; CNRS, Institut de Pharmacologie et de Biologie Structurale; and Université de Toulouse, Toulouse, FranceAuthors' Affiliations: INSERM UMR S935, Poitiers and Villejuif; Université Paris-Sud 11, Orsay; INSERM U1082; Université de Poitiers; Service d'Immunologie et Inflammation; CHU de Poitiers; Etablissement Français du Sang Centre-Atlantique, site de Poitiers; Service d'Oncologie Hématologique et Thérapie Cellulaire; INSERM-CIC1402; Service de Cancérologie Biologique; Service d
| |
Collapse
|
10
|
Aggoune D, Tosca L, Sorel N, Bonnet ML, Dkhissi F, Tachdjian G, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscience 2014; 1:57-68. [PMID: 25593988 PMCID: PMC4295758 DOI: 10.18632/oncoscience.9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2013] [Accepted: 01/20/2014] [Indexed: 01/04/2023] Open
Abstract
Tyrosine kinase inhibitors (TKIs) have profoundly changed the natural history of chronic myeloid leukemia (CML). However, acquired resistance to imatinib, dasatinib or nilotinib (1st and 2nd generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These drugs are ineffective on the T315I gatekeeper substitution, which remains sensitive to 3rd generation TKI ponatinib. It has recently been suggested that the hematopoietic niche could protect leukemic cells from targeted therapy. In order to investigate the role of a stromal niche in mutation-related resistance, we developed a niche-based cell mutagenesis assay. For this purpose, ENU (N-ethyl-N-nitrosourea)-exposed UT-7 cells expressing non-mutated or T315I-mutated BCR-ABL1 were cultured with or without murine MS-5 stromal cells and in the presence of imatinib, dasatinib, nilotinib, or ponatinib. In the assays relative to 1st and 2nd generation TKIs, which were performed on non-mutated BCR-ABL1 cells, our data highlighted the increasing efficacy of the latter, but did not reveal any substantial effect of the niche. In ponatinib assays performed on both non-mutated and T315I–mutated BCR-ABL1 cells, an increased number of resistant clones were observed in the presence of MS-5. Present data suggested that T315I mutants need either compound mutations (e.g. E255K/T315I) or a stromal niche to escape from ponatinib. Using array-comparative genomic hybridization experiments, we found an increased number of variations (involving some recurrent chromosome regions) in clones cultured on MS-5 feeder. Overall, our study suggests that the hematopoietic niche could play a crucial role in conferring resistance to ponatinib, by providing survival signals and favoring genetic instability.
Collapse
Affiliation(s)
| | - Lucie Tosca
- INSERM, U935, F-94800, Villejuif, France ; Université Paris-Sud 11, F-94270 Le Kremlin-Bicêtre, France ; Hôpital Antoine Béclère, Service d'Histologie-Embryologie-Cytogénétique, F-92140 Clamart, France
| | - Nathalie Sorel
- INSERM, U935, F-86000 Poitiers, France ; CHU de Poitiers, Service de Cancérologie Biologique, F-86000 Poitiers, France
| | | | | | - Gérard Tachdjian
- INSERM, U935, F-94800, Villejuif, France ; Université Paris-Sud 11, F-94270 Le Kremlin-Bicêtre, France ; Hôpital Antoine Béclère, Service d'Histologie-Embryologie-Cytogénétique, F-92140 Clamart, France
| | - Annelise Bennaceur-Griscelli
- INSERM, U935, F-94800, Villejuif, France ; Université Paris-Sud 11, F-94270 Le Kremlin-Bicêtre, France ; Hôpital Paul Brousse, Service d'Hématologie Biologique, F-94800 Villejuif, France
| | - Jean-Claude Chomel
- INSERM, U935, F-86000 Poitiers, France ; CHU de Poitiers, Service de Cancérologie Biologique, F-86000 Poitiers, France
| | - Ali G Turhan
- INSERM, U935, F-86000 Poitiers, France ; INSERM, U935, F-94800, Villejuif, France ; Université Paris-Sud 11, F-94270 Le Kremlin-Bicêtre, France ; Hôpital Bicêtre, Service d'Hématologie Biologique, F-94270 Le Kremlin Bicêtre, France
| |
Collapse
|
11
|
Gombert JM, Levescot A, Flamant S, Jacomet F, Basbous S, Féraud O, Bonnet ML, Giraud C, Roy L, Barra A, Turhan A, Guilhot F, Herbelin A. Bcr/Abl-induced deregulation of the IL-33/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients (P6284). The Journal of Immunology 2013. [DOI: 10.4049/jimmunol.190.supp.46.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Although it is generally acknowledged that cytokines regulate normal hematopoiesis in an autocrine/paracrine fashion, their possible role in chronic myeloid leukemia (CML) and resistance to imatinib mesylate (IM) treatment remain poorly investigated. Here, we report that CD34(+) progenitors from CML patients at diagnosis are selectively targeted by the cytokine/alarmin IL-33. Indeed, CML CD34(+) progenitors up-regulate their cell surface expression of the IL-33-specific receptor chain ST2, proliferate and produce cytokines in response to IL-33, conversely to CD34(+) cells from healthy individuals. Moreover, ST2 overexpression is normalized following IM therapy, while IL-33 counteracts in-vitro IM-induced growth arrest in CML CD34(+) progenitors via re-activation of the STAT5 pathway. Clinically, CML is associated with high circulating levels of soluble ST2, commonly used as a functional signature of IL-33 signaling in vivo. Taken together, our results support the hypothesis that the IL-33/ST2 pathway facilitates Bcr/Abl-induced leukemogenesis and contributes to IM resistance in CML patients.
Collapse
Affiliation(s)
- Jean-Marc Gombert
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 3Service d’Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
| | - Anaïs Levescot
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 2Université Paris Sud 11, Orsay, France
| | | | - Florence Jacomet
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 3Service d’Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
| | - Sara Basbous
- 3Service d’Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
| | - Olivier Féraud
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 2Université Paris Sud 11, Orsay, France
| | - Marie-Laure Bonnet
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
| | - Christine Giraud
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
- 6Etablissement Français du Sang Centre-Atlantique, site de Poitiers, Poitiers, France
- 7Service d’Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France
| | - Lydia Roy
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
- 7Service d’Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France
- 8Centre d’investigation clinique INSERM-P-802, INSERM, Poitiers, France
| | - Anne Barra
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 3Service d’Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
| | - Ali Turhan
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
- 9Service d’Hématologie et d'Oncologie Biologique, CHU de Poitiers, Poitiers, France
| | - François Guilhot
- 4CHU de Poitiers, Poitiers, France
- 5Université de Poitiers, Poitiers, France
- 7Service d’Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France
- 8Centre d’investigation clinique INSERM-P-802, INSERM, Poitiers, France
| | - André Herbelin
- 1INSERM UMR S-935, INSERM, Poitiers, France
- 2Université Paris Sud 11, Orsay, France
- 4CHU de Poitiers, Poitiers, France
| |
Collapse
|
12
|
Tsuchiizu M, Omori Y, Suzumura Y, Bonnet ML, Robert V. Ab initio derivation of multi-orbital extended Hubbard model for molecular crystals. J Chem Phys 2012; 136:044519. [PMID: 22299903 DOI: 10.1063/1.3678307] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
From configuration interaction (CI) ab initio calculations, we derive an effective two-orbital extended Hubbard model based on the gerade (g) and ungerade (u) molecular orbitals (MOs) of the charge-transfer molecular conductor (TTM-TTP)I(3) and the single-component molecular conductor [Au(tmdt)(2)]. First, by focusing on the isolated molecule, we determine the parameters for the model Hamiltonian so as to reproduce the CI Hamiltonian matrix. Next, we extend the analysis to two neighboring molecule pairs in the crystal and we perform similar calculations to evaluate the inter-molecular interactions. From the resulting tight-binding parameters, we analyze the band structure to confirm that two bands overlap and mix in together, supporting the multi-band feature. Furthermore, using a fragment decomposition, we derive the effective model based on the fragment MOs and show that the staking TTM-TTP molecules can be described by the zig-zag two-leg ladder with the inter-molecular transfer integral being larger than the intra-fragment transfer integral within the molecule. The inter-site interactions between the fragments follow a Coulomb law, supporting the fragment decomposition strategy.
Collapse
|
13
|
|
14
|
Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan AG. Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma 2010; 51:2103-11. [DOI: 10.3109/10428194.2010.520774] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
15
|
Bonnet ML, Robert V, Tsuchiizu M, Omori Y, Suzumura Y. Intramolecular charge ordering in the multi molecular orbital system (TTM-TTP)I3. J Chem Phys 2010; 132:214705. [DOI: 10.1063/1.3432764] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JEJ. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010; 95:1325-33. [PMID: 20460641 DOI: 10.3324/haematol.2009.020636] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the effect of imatinib on miRNA expression in vivo has not been thoroughly examined. DESIGN AND METHODS Using a TaqMan Low-Density Array system, we analyzed miRNA expression in blood samples from newly diagnosed chronic myeloid leukemia patients before and within the first two weeks of imatinib therapy. Quantitative real-time PCR was used to validate imatinib-modulated miRNAs in sequential primary chronic myeloid leukemia samples (n=11, plus 12 additional validation patients). Bioinformatic target gene prediction analysis was performed based on changes in miRNA expression. RESULTS We observed increased expression of miR-150 and miR-146a, and reduced expression of miR-142-3p and miR-199b-5p (3-fold median change) after two weeks of imatinib therapy. A significant correlation (P<0.05) between the Sokal score and pre-treatment miR-142-3p levels was noted. Expression changes in the same miRNAs were consistently found in an additional cohort of chronic myeloid leukemia patients, as compared to healthy subjects. Peripheral blood cells from chronic phase and blast crisis patients displayed a 30-fold lower expression of miR-150 compared to normal samples, which is of particular interest since c-Myb, a known target of miR-150, was recently shown to be necessary for Bcr-Abl-mediated transformation. CONCLUSIONS We found that imatinib treatment of chronic myeloid leukemia patients rapidly normalizes the characteristic miRNA expression profile, suggesting that miRNAs may serve as a novel clinically useful biomarker in this disease.
Collapse
Affiliation(s)
- Stéphane Flamant
- Gene and Stem Cell Therapy Program, Centenary Institute, Locked Bag No 6, Newtown, NSW 2042, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Evangelio E, Bonnet ML, Cabañas M, Nakano M, Sutter JP, Dei A, Robert V, Ruiz-Molina D. Coexistence of Two Thermally Induced Intramolecular Electron Transfer Processes in a Series of Metal Complexes [M(Cat-N-BQ)(Cat-N-SQ)]/[M(Cat-N-BQ)2] (M=Co, Fe, and Ni) bearing Non-Innocent Catechol-Based Ligands: A Combined Experimental and Theoretical S. Chemistry 2010; 16:6666-77. [DOI: 10.1002/chem.200902568] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
18
|
Jia QX, Bonnet ML, Gao EQ, Robert V. Competing Large and Small Angles in a Double End-On Azido Copper(II) Binuclear Complex: A Combined Experimental and Theoretical Study of Magnetic Interactions. Eur J Inorg Chem 2009. [DOI: 10.1002/ejic.200900205] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
19
|
Belliard A, Mauco G, Bonnet ML, Hauet T, Macchi L. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes. Cell Mol Biol (Noisy-le-grand) 2008; 54 Suppl:OL1077-OL1082. [PMID: 19149969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2008] [Accepted: 12/29/2008] [Indexed: 05/27/2023]
Abstract
Platelets form heterotypic complexes with circulating monocytes, inducing the expression of the procoagulant Tissue Factor (TF) that leads to thrombin generation. We investigated the potential preventive effect of melagatran, a direct anti-thrombin drug, on TF expression by platelet/monocyte heterotypic complexes (PMHC) from healthy human donors. Flow cytometry and western blot analysis were performed to characterize surface and total TF protein expression in PMHC in venous blood samples drawn in the presence of heparin or heparin and melagatran (4 microM). Addition of melagatran significantly lowered the percentage of TF positive PMHC (2.6+/-0.3 vs. 5.9+/-0.7 %, p<0.01). This was not due to a melagatran-induced decrease in activation of the platelets associated with monocytes in PMHC. Indeed, melagatran effect on TF expression was accompanied by an increase in cell surface P-selectin expression in PMHC (95.6+/-1.9 vs. 48+/-18 %, p<0.001), suggesting that platelet were actually more activated in PMHC from the melagatran-treated samples. Western blot analysis of PBMC extracts suggested that melagatran specifically targeted a (54kD) form of TF in monocytes. Although further investigation is warranted, these data suggest that melagatran decreases TF expression in PMHC.
Collapse
|
20
|
Suaud N, Bonnet ML, Boilleau C, Labèguerie P, Guihéry N. Light-Induced Excited Spin State Trapping: Ab Initio Study of the Physics at the Molecular Level. J Am Chem Soc 2008; 131:715-22. [DOI: 10.1021/ja805626s] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Nicolas Suaud
- Université de Toulouse, UPS, Laboratoire de Chimie et Physique Quantiques, IRSAMC, 31062 Toulouse, France, CNRS, UMR 5626, France, and Laboratoire de Chimie, UMR 5182, Ecole normale supérieure de Lyon, 46 allée d’Italie, 69364 Lyon Cédex 07, France
| | - Marie-Laure Bonnet
- Université de Toulouse, UPS, Laboratoire de Chimie et Physique Quantiques, IRSAMC, 31062 Toulouse, France, CNRS, UMR 5626, France, and Laboratoire de Chimie, UMR 5182, Ecole normale supérieure de Lyon, 46 allée d’Italie, 69364 Lyon Cédex 07, France
| | - Corentin Boilleau
- Université de Toulouse, UPS, Laboratoire de Chimie et Physique Quantiques, IRSAMC, 31062 Toulouse, France, CNRS, UMR 5626, France, and Laboratoire de Chimie, UMR 5182, Ecole normale supérieure de Lyon, 46 allée d’Italie, 69364 Lyon Cédex 07, France
| | - Pierre Labèguerie
- Université de Toulouse, UPS, Laboratoire de Chimie et Physique Quantiques, IRSAMC, 31062 Toulouse, France, CNRS, UMR 5626, France, and Laboratoire de Chimie, UMR 5182, Ecole normale supérieure de Lyon, 46 allée d’Italie, 69364 Lyon Cédex 07, France
| | - Nathalie Guihéry
- Université de Toulouse, UPS, Laboratoire de Chimie et Physique Quantiques, IRSAMC, 31062 Toulouse, France, CNRS, UMR 5626, France, and Laboratoire de Chimie, UMR 5182, Ecole normale supérieure de Lyon, 46 allée d’Italie, 69364 Lyon Cédex 07, France
| |
Collapse
|
21
|
Villalva C, Sorel N, Bonnet ML, Guilhot J, Mayeur-Rousse C, Guilhot F, Chomel JC, Turhan AG. Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma 2008; 49:984-8. [PMID: 18464118 DOI: 10.1080/10428190801942360] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The murine equivalent of neutrophil gelatinase-associated lipocalin (NGAL) was previously found to be increased by BCR-ABL expression in murine models of chronic myeloid leukemia (CML). Our study evaluates, in CML patients at various clinical stages, the levels of NGAL mRNA in blood samples and protein in sera. A highly significant increase of mRNA expression and protein secretion was shown in patients at diagnosis. The parallel expression of NGAL and BCR-ABL at the early stage of CML process allows us to suggest that NGAL could play an important role in the physiopathology of CML.
Collapse
Affiliation(s)
- Claire Villalva
- Service d'Hématologie et Oncologie Biologique - EA 3805, CHU de Poitiers, Université de Poitiers, France
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Bonnet ML, Aronica C, Chastanet G, Pilet G, Luneau D, Mathonière C, Clérac R, Robert V. Nickel(II) Chain with Alternating End-On/End-to-End Single Azido Bridges: A Combined Structural, Magnetic, and Theoretical Study. Inorg Chem 2007; 47:1127-33. [DOI: 10.1021/ic702012r] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Marie-Laure Bonnet
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Christophe Aronica
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Guillaume Chastanet
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Guillaume Pilet
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Dominique Luneau
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Corine Mathonière
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Rodolphe Clérac
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| | - Vincent Robert
- Laboratoire de Chimie (UMR 5182), Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69364 Lyon cedex 07, France, Laboratoire des Multimatériaux et Interfaces (UMR 5615), Université Claude Bernard Lyon 1, 69622 Villeurbanne cedex, France, Institut de Chimie de la Matière Condensée de Bordeaux (UPR-CNRS 9048) Université Bordeaux 1, CNRS, 87 Avenue du Dr. A. Schweitzer, 33608 Pessac cedex, France, and Université Bordeaux 1, CNRS, Centre de Recherches Paul Pascal (CRPP) UPR-8641, 115 Avenue du Dr. A
| |
Collapse
|
23
|
Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006; 134:171-9. [PMID: 16846476 DOI: 10.1111/j.1365-2141.2006.06161.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Chronic myeloid leukaemia (CML) is characterised by a progression from a chronic towards an acute phase. We previously reported that signal transducer and activator of transcription 3 (STAT3), a major oncogenic signalling protein, is the target of p210-BCR-ABL in a murine embryonic stem (ES) cell model and in primary CD34+ CML cells. This activation was associated with inhibition of differentiation in ES cells. The present study found that BCR-ABL greatly phosphorylated STAT3 Ser727 residue and, to a lesser extent, Tyr705 residue in BCR-ABL-expressing cell lines (UT7-p210, MO7E-p210, and K562) and in primary CD34+ CML cells. Using BCR-ABL mutants, it was shown that BCR-ABL tyrosine kinase activity and its Tyr177 residue were necessary for STAT3 Ser727 phosphorylation. Constitutive STAT3 Tyr705 phosphorylation was associated with constitutive phosphorylation of Janus kinase (JAK)1 and JAK2, and was inhibited by the JAK inhibitor AG490, suggesting the involvement of JAK proteins in this process. Specific MEK [mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) kinase] inhibitors PD98056 and UO126, as well as the use of a dominant-negative form of MEK1 abrogated STAT3 Ser727 phosphorylation, suggesting involvement of MAP-Kinase/Erk pathway. Inhibition of BCR-ABL with imatinib mesylate led to a dose-dependent downregulation of total STAT3 protein and mRNA, suggesting that BCR-ABL is involved in the transcriptional regulation of STAT3. Targeting JAK, MEK and STAT3 pathways could therefore be of therapeutic value, especially in advanced stage CML.
Collapse
MESH Headings
- Antigens, CD34/analysis
- Fusion Proteins, bcr-abl
- Gene Expression Regulation, Neoplastic
- Humans
- Janus Kinase 1
- Janus Kinase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism
- MAP Kinase Kinase Kinases/physiology
- Neoplasm Proteins/metabolism
- Phosphorylation
- Protein-Tyrosine Kinases/physiology
- Proto-Oncogene Proteins/physiology
- RNA, Messenger/genetics
- STAT3 Transcription Factor/genetics
- STAT3 Transcription Factor/metabolism
- Signal Transduction
- Transcription, Genetic
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- Paul Coppo
- INSERM U362 Unité Hématopoïèse et Cellules Souches, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
A new selected-configuration interaction method is proposed, based on the use of local orbitals. A corresponding code has been written, which is devoted to CI calculations of rather large systems (about 50-100 carbon-like atoms). Taking advantage of the locality, and then of the fact that interactions vanish when the distance is large, the dimension of the CI space is largely reduced. The determinants that would be created by long range excitations are expected to have a small weight in the wave function and are therefore eliminated. This selected excitation CI space is particularly suited for large molecules. It is tested on large polyene chains and on a transition metal complex. For large enough systems, the CPU time saving is important and, what is more noticeable, calculations that were impossible to perform without selection are feasible in this approach.
Collapse
Affiliation(s)
- Benoît Bories
- Laboratoire de Chimie et Physique Quantiques, IRSAMC, Université Paul Sabatier, 118, Route de Narbonne, Toulouse Cedex 31062, France
| | | | | |
Collapse
|
25
|
Tourino C, Pflumio F, Novault S, Massé A, Guiller M, Bonnet ML, Valteau-Couanet D, Hartmann O, Vainchenker W, Beaujean F, Coulombel L, Turhan AG. Efficient ex vivo expansion of NOD/SCID-repopulating cells with lympho-myeloid potential in hematopoietic grafts of children with solid tumors. Hematol J 2005; 2:108-16. [PMID: 11424003 DOI: 10.1038/sj/thj/6200083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/10/2000] [Accepted: 11/25/2000] [Indexed: 11/09/2022]
Abstract
INTRODUCTION The ex vivo expansion of hematopoietic grafts could be an important therapeutic tool for accelerating hematopoietic recovery after administration of high-dose chemotherapy regimens. The fate of the long-term repopulating cells during the ex vivo manipulation of grafts is a critical issue and will ultimately define the clinical applicability of this technology to hematopoietic transplantation. MATERIALS AND METHODS To study the effects of a clinically applicable ex vivo expansion protocol in the proliferative potential of the most primitive human hematopoietic cells, both LTC-IC and NOD/SCID-RC assays were used to determine LTC-IC and NOD/SCID-RC contents of hematopoietic grafts, both before and after expansion (SCF, IL-3, PEG-MGDF Flt3-L and 5% AB serum), in four children with non-hematological malignancies. RESULTS The mean percentage of CD34+ cells after expansion was 16%. The numbers of nucleated cells increased 20-fold with a mean three-fold increase in the numbers of CD34+ cells during the expansion period. The CFC content of the samples showed a mean 11-fold increase (range: 5-17) after ex vivo expansion. The primitive hematopoietic stem cell content of the expanded cell fraction evaluated by LTC-IC assays was found to be increased in two patients out of three, with maintenance of the LTC-IC frequency in the third patient. The NOD/SCID-RC potential, evaluated in five experiments from four patients using 109 mice injected 5-6 weeks earlier with human hematopoietic cells, increased from a mean percentage of 36% (range: 7-75%) before expansion, to a mean percentage of 70% (range: 37-100%) after expansion (P < 0.00001). The frequency of NOD/SCID-RC calculated with pooled data from all patients was 1/80,000 at day 0 and 1/40,000 after seven days of culture. The full phenotypic analysis of human hematopoietic cells obtained in NOD/SCID mice injected with expanded cells showed the presence of significant numbers of CD34+, CD19+ and CD15+ cells, suggesting the persistent lympho-myeloid potential of the expanded hematopoietic cells. CONCLUSION Our results suggest that efficient expansion of NOD/SCID-RC with lympho-myeloid potential can be achieved not only in cord blood or normal marrow as previously reported, but also in hematopoietic grafts obtained from children exposed to high-dose chemotherapy.
Collapse
Affiliation(s)
- C Tourino
- Departamento Basico de Medicina, Hospital de Clinicas, Montevideo, Uruguay
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Soenen-Cornu V, Tourino C, Bonnet ML, Guillier M, Flamant S, Kotb R, Bernheim A, Bourhis JH, Preudhomme C, Fenaux P, Turhan AG. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene 2005; 24:2441-8. [PMID: 15735749 DOI: 10.1038/sj.onc.1208405] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells (MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n=12) and have purified their CD34+CD38- and CD34+CD38+ counterparts (n=7) before using MC as a short- and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.
Collapse
|
27
|
Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004; 323:728-30. [PMID: 15381060 DOI: 10.1016/j.bbrc.2004.08.169] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2004] [Indexed: 11/24/2022]
Abstract
To study the hierarchical levels of stem cell targets for ABL-kinase domain mutations in CML, highly purified CD34+CD38- and CD34+CD38+ cell populations and their LTC-IC-derived progeny were analyzed in four patients at diagnosis (n=1) or in advanced phases (n=3) of their disease. In the single patient with early phase CML who later developed an Imatinib Mesylate-resistance and a Y253H mutation, no mutation was detectable in purified cell fractions analyzed at diagnosis nor in their LTC-IC-derived progeny. In contrast, in three patients in advanced phase CML, ABL-kinase mutations demonstrated in peripheral blood cells by sequencing (Q252E and M351T) were detectable in the FACS-sorted cells and became amplified in the LTC-IC-derived progeny of the primitive cells. These findings demonstrate that in late CP or advanced CML, ABL-kinase mutations occur as an intraclonal event in the primitive Ph1+ stem cell compartments with progression of this clone towards IM-resistant blast phase.
Collapse
MESH Headings
- Antineoplastic Agents/administration & dosage
- Benzamides
- Cell Differentiation/drug effects
- Cell Differentiation/genetics
- Cells, Cultured
- Drug Resistance/genetics
- Enzyme Inhibitors/administration & dosage
- Fusion Proteins, bcr-abl/genetics
- Gene Expression Regulation, Neoplastic/drug effects
- Genetic Predisposition to Disease/genetics
- Genetic Testing/methods
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Mutation
- Phosphotransferases/antagonists & inhibitors
- Phosphotransferases/genetics
- Piperazines/administration & dosage
- Protein Structure, Tertiary
- Pyrimidines/administration & dosage
- Sequence Analysis, Protein
- Stem Cells/drug effects
- Stem Cells/enzymology
- Stem Cells/pathology
- Structure-Activity Relationship
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- N Sorel
- Laboratory of Hematology, Hôpital de la Miletrie, CHU Poitiers, France
| | | | | | | | | | | |
Collapse
|
28
|
Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfir K, Frascogna V, Turhan AG, Bourhis J. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 2004; 91:1735-41. [PMID: 15494718 PMCID: PMC2409959 DOI: 10.1038/sj.bjc.6602190] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Chronic myelogenous leukaemia (CML) is a clonal malignancy of the pluripotent haematopoietic stem cell, characterised by an uncontrolled proliferation and expansion of myeloid progenitors expressing a fusion oncogene, BCR-ABL, the molecular counterpart of the Ph1 chromosome. The tyrosine kinase (TK) activity of BCR-ABL is known to activate several major signalling pathways in malignant cells, including Ras, JAK/STAT and PI3K/Akt with evidence of proteasome-mediated degradation of other targets such as the DNA repair protein DNA-PKcs and cyclin-dependent kinases inhibitor p27. Targeting these abnormalities by blocking TK of BCR-ABL with STI571 provided a promising approach for the therapy of CML. The recent development of resistance to STI571 illustrates, however, that the use of other TK inhibitors could be of major interest for therapeutic purposes. To this end, the TK inhibitor Tyrphostin AG1024 was used to evaluate effect on regulation of BCR-ABL expression, inhibition of cell proliferation and tumour formation in vivo in human and murine BCR-ABL expressing cell lines. Tyrphostin AG1024 was shown to downregulate expression of BCR-ABL and P-Akt, and to upregulate DNA-PKcs expression. In addition, Tyrphostin AG1024 was able to inhibit cell proliferation, and delay tumour growth in vivo. Thus, AG1024 is able to interfere with three major targets of BCR-ABL in leukaemic cells. Interestingly, Tyrphostin AG1024 was also effective against cells resistant to STI571 by distinct mechanisms including Bcr-Abl mutation. Therefore, these data suggest that Tyrphostin AG1024 could represent the basis of a novel therapy for STI571 refractory CML.
Collapse
MESH Headings
- Animals
- Antineoplastic Agents/therapeutic use
- Benzamides
- Cell Proliferation/drug effects
- DNA-Activated Protein Kinase
- DNA-Binding Proteins/antagonists & inhibitors
- Drug Resistance, Neoplasm
- Enzyme Inhibitors/therapeutic use
- Fusion Proteins, bcr-abl
- Gene Expression Regulation, Leukemic
- Humans
- Imatinib Mesylate
- Leukemia, Erythroblastic, Acute/drug therapy
- Leukemia, Erythroblastic, Acute/metabolism
- Mice
- Mice, Nude
- Neoplasm Recurrence, Local/drug therapy
- Neoplasm Recurrence, Local/metabolism
- Neoplasm Recurrence, Local/pathology
- Nuclear Proteins
- Phosphorylation
- Piperazines/pharmacology
- Protein Serine-Threonine Kinases/antagonists & inhibitors
- Protein Serine-Threonine Kinases/metabolism
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Protein-Tyrosine Kinases/metabolism
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-akt
- Pyrimidines/pharmacology
- Tumor Cells, Cultured
- Tyrphostins/therapeutic use
Collapse
Affiliation(s)
- E Deutsch
- Laboratoire UPRES EA No 27-10, Radiosensibilité des tumeurs et tissus sains, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cédex, France.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003; 101:4583-8. [PMID: 12576338 DOI: 10.1182/blood-2002-10-3011] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BCR-ABL fusion oncogene is the molecular hallmark of chronic myelogenous leukemia (CML), a condition characterized by a progression from a chronic to acute phase leukemia because of secondary genetic events, the nature of which remains largely unknown. Here, we report that the expression of the p210 BCR-ABL fusion protein leads to a down-regulation of BRCA1 protein, a gene product involved in the maintenance of genome integrity. BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. Similarly, stable transfection-enforced expression of p210 protein in established hematopoietic cell lines leads to severe BRCA1 depletion. The lack of significant change in BRCA1 mRNA level in cells expressing p210 supports the hypothesis that the regulation of BRCA1 protein level occurs after transcription. It is abolished on exposure of the cells to STI571 and by mutation in the adenosine triphosphate (ATP) pocket of p210 and thus seems to require the tyrosine kinase activity of BCR-ABL. Cell lines expressing high levels of BCR-ABL display an increased rate of sister chromatid exchange and chromosome aberrations after ionizing radiation. These findings reveal a novel link between the oncoprotein BCR-ABL and the tumor-suppressor protein BRCA1.
Collapse
Affiliation(s)
- Eric Deutsch
- Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Dugray A, Geay JF, Foudi A, Bonnet ML, Vainchenker W, Wendling F, Louache F, Turhan AG. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia 2001; 15:1658-62. [PMID: 11587226 DOI: 10.1038/sj.leu.2402225] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The development of chronic myelogenous leukemia (CML) models in mice using an inducible BCR-ABL gene has been hampered by the requirement of sequential expression of tTA (Tet repressor-VP16 fusion protein) and Tet-OP sequences in the same cells after separate transfection. This double transfection strategy is time consuming as it requires screening of many hundreds of individual clones and cannot be applied to primary hematopoietic cells. To generate a tetracycline-inducible BCR-ABL retrovirus, we have subcloned BCR-ABL p210 cDNA in the SIN-Retro-TET vector, which allows regulated expression of a gene of interest in a single autoregulatory cassette, containing both tTA and Tet OP sequences. Retroviral particles were obtained by transfecting the SIN-BCR-ABL p210 construct into the 293 cells and by VSVG pseudotyping. To determine the functionality of the retrovirus, the IL-3-dependent murine Ba/F3 cell line was retrovirally transduced and clones were grown in the absence of both IL-3 (to select for transformed cells) and a tetracycline analog, doxycycline (to induce BCR-ABL expression). Using this technique, polyclonal Ba/F3 cells and several growth factor-independent Ba/F3 clones expressing BCR-ABL were obtained within 2-3 weeks. A single dose of doxycycline added to the medium (1 microg/ml), induced in different clones, a reduction of BCR-ABL protein levels by 60-90% at 24 h, leading to cell death in the absence of IL-3. In several individual clones, BCR-ABL expression was further reduced to become almost undetectable at 48 h. The doxycycline-regulated BCR-ABL expression was stable, as many clones maintained in culture for >8 months showed a persistent inhibitory response to doxycycline addition in the medium. In in vivo experiments, subcutaneous injection of 2 x 10(6) Ba/F3-SIN p210 cells in nude mice induced visible tumors in 2 weeks and all established tumors completely regressed upon addition of doxycycline in the drinking water (200 microg/ml). To determine the functionality of the inducible BCR-ABL retrovirus in vivo, primary Lin- bone marrow cells were transduced with SIN-p210 and transplanted in lethally irradiated mice. All transplanted mice had successful hematopoietic reconstitution and BCR-ABL integration was found in the peripheral blood of seven out of 14 mice available for long-term analysis (>6 months). However, despite evidence of retrovirus-mediated gene transfer, there was no evidence of leukemia, due either to low viral titers or to the relative inefficiency of the minimal CMV promoter in primary hematopoietic cells. Thus, these results demonstrate for the first time, to our knowledge, the feasibility to generate an inducible BCR-ABL retrovirus in a single step, in the context of an immortalized cell line. Our data suggest that with further improvements of the retrovirus-mediated gene transfer technology, it might be possible to generate inducible leukemia models in mice by the use of single retroviral constructs.
Collapse
Affiliation(s)
- A Dugray
- INSERM U362, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Ahmed M, Dusanter-Fourt I, Dugray A, Dubrez L, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Solary E, Vainchenker W, Turhan AG. BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5. Leuk Lymphoma 2001; 42:445-55. [PMID: 11699409 DOI: 10.3109/10428190109064601] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Recent experimental data suggest that one of the major effects of BCR-ABL gene expression in hematopoietic cells is the inhibition of apoptosis. Although the exact mechanisms of this phenomenon are not clear, it is thought to be related to the fact that BCR-ABL induces several signalling pathways also activated by growth factors. In order to determine the anti-apoptotic role of BCR-ABL in a hematopoietic cell line and to by-pass the influence of cytokine-dependence, BCR-ABL gene was expressed in the autonomously growing myelomonocytic U937 cell line using retroviral vectors. There was no resistance to apoptosis induced by either serum deprivation or different doses of etoposide in any U937 clones expressing BCR-ABL protein. In addition to serum deprivation and etoposide, BCR-ABL-expressing clones were not protected from apoptosis induced by TNF, ceramide-C2 and FAS-cross-linking. BCL2 expression was absent in U937 cells and BAX levels were identical between Neo and BCR-ABL clones. To further investigate the mechanisms of this phenomenon, band-shift assays were performed to detect activation of STAT molecules. No constitutive activation of STATs was detected in either NeoR or BCR-ABL-U937 cells, although both IFN-gamma and GM-CSF activated STAT1 and STAT5, respectively, with similar kinetics in both NeoR and BCR-ABL-U937 cells. In addition, the GM-CSF-induced-STAT5 activation was found to be weakened in all clones expressing BCR-ABL. In both control NeoR and BCR-ABL-transfected clones, band-shift assays revealed the presence of an abnormal truncated STAT5 recognized only by an anti-N-terminal but not by an anti-C-Terminal STAT5 antibody. These findings suggest a possible link between the absence of anti-apoptotic potential of BCR-ABL and abnormalities of the STAT5 pathway, including, absence of constitutive activation of STAT5, inhibition of GM-CSF-induced STAT5 activation and expression of a carboxyl-terminal-truncated STAT5.
Collapse
Affiliation(s)
- M Ahmed
- Institut Gustave Roussy, Inserm U362 and Translational Research Laboratory, PR-1 39, Rue Camille Desmoulins 94805, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Tourino C, Pflumio F, Novault S, Massé A, Guiller M, Bonnet ML, Valteau-Couanet D, Hartmann O, Vainchenker W, Beaujean F, Coulombel L, Turhan AG. Efficient ex vivo expansion of NOD/SCID-repopulating cells with lympho-myeloid potential in hematopoietic grafts of children with solid tumors. ACTA ACUST UNITED AC 2001. [DOI: 10.1038/sj.thj.6200083] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
33
|
Issaad C, Ahmed M, Novault S, Bonnet ML, Bennardo T, Varet B, Vainchenker W, Turhan AG. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia 2000; 14:662-70. [PMID: 10764152 DOI: 10.1038/sj.leu.2401730] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
There is currently no satisfactory model allowing analysis of dose-effect relationships of BCR-ABL proteins in human hematopoietic cells. To study comparatively the proliferative, differentiative and anti-apoptotic actions of different levels of BCR-ABL proteins in the context of the same cellular background, we have introduced the BCR-ABL gene into the GM-CSF-dependent pluripotent human cell line UT-7. Individual clones expressing BCR-ABL were analyzed by Western blots. After normalization to equivalent levels of endogenous ABL protein, 14 clones always grown in GM-CSF were found to express low but variable levels of BCR-ABL whereas two clones selected in the absence of GM-CSF expressed very high levels of BCR-ABL. All low-level BCR-ABL expressing clones exhibited a behavior similar to that of the GM-CSF-dependent parental cells as they ceased to proliferate upon growth factor deprivation and showed a strong proliferative response upon GM-CSF addition. One out of 14 clones showed progressive GM-CSF independence during culture over several weeks and was found to have a significant increase of BCR-ABL expression at that time. The resistance of this clone (E8-2) to different apoptotic stimuli was found to be increased as compared to its low BCR-ABL-expressing counterpart (E8-1) and similar to that observed in clones with very high levels of BCR-ABL (UT-7/9 and UT-7/11) which were totally resistant to apoptotic stimuli. When injected into nude mice, parental UT-7 cells and clones with low-level of BCR-ABL were not tumorigenic over 10 weeks of observation whereas UT-7 clones with high levels of BCR-ABL (UT-7/9, UT-7/11 and UT-7/E8-2) induced aggressive tumors in 2-4 weeks with a significant correlation between the amount of BCR-ABL protein and the rate of tumor growth. In conclusion, the establishment of an in vitro and in vivo CML model using UT-7 cells suggests for the first time in human cells, that the fully transformed phenotype induced by BCR-ABL requires high levels of BCR-ABL expression. These findings suggest that variable levels of BCR-ABL in primary patient cells could also be responsible for the different phenotypic features seen in chronic and acute phases of CML, such as the differentiation ability induced by growth factors.
Collapse
Affiliation(s)
- C Issaad
- INSERM U362, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Turhan AG, Bourhis JH, Bonnet ML, Novault S, Bayle C, Bennaceur A, Vainchenker W, Pico JL, Beaujean F. Unfractionated peripheral blood stem cell autografts and CD(34+)-enriched autografts have similar long-term culture initiating capacity in multiple myeloma. Hematol Cell Ther 1999; 41:197-204. [PMID: 10651119 DOI: 10.1007/s00282-999-0197-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
CD(34+)-enriched peripheral blood stem cells (PBSC) are increasingly being used as an autograft in patients with multiple myeloma (MM). The rationale for the use of the CD34+-enriched fraction in MM is the ability to obtain a graft with a significant reduction of contamination by plasma cells. However, the effect of such a manipulation on the proliferating potential of the engrafted cells is not known. We wished to study, as part of a randomized trial comparing the outcome in MM patients transplanted with either CD(34+)-enriched cells or unfractionated PBSC, the primitive hematopoietic cell content of the autografts using long-term culture initiating cell (LTC-IC) assays in 7 MM patients. In 3 patients CD(34+)cell-enriched fraction was compared to unfractionated PBSC whereas in the remaining 4 patients the LTC-IC assay was performed on total PBSC. The mean percentage of CD34+ cells of the CD34+ selected fraction in three patients was 82% (range 71%-96%) whereas the same percentage in PBSC varied from 0.6% to 10% in 4 patients (mean: 4.2%). Out of three patients transplanted with CD34+ cell fraction, two patients were found to have a very similar LTC-IC generating potential in their CD34+ versus PBSC fractions as this was assessed by the clonogenic cell output at week+5 per 10(4) CD34+ cells initiating the culture (PBSC: 92 and 168 and CD34+ fraction: 102 and 16, respectively) whereas one patient had a slightly different values (PBSC: 51 and CD34+ fraction: 103). When the PBSC fraction was compared in all 7 patients, the LTC-IC generation potential was very heterogenous, varying from 1.4 to 168. To determine if the selection procedure influences the numbers of LTC-IC's in both fractions, we have performed limiting dilution assays to determine both the frequency of distribution of hematopoietic colonies and the frequency of LTC-IC's in two patients. The frequency of distribution of hematopoietic colonies was linear in both CD34+ and PBSC fractions as was the frequency of LTC-IC when the corrections were made with regard to the CD34+ cell-content of the cultures (1/20). Our results indicate that the CD34+ selection procedure used in all three patients (Ceprate) is not deleterious for the generation of LTC-IC's and these findings support the rationale for the use of this procedure in multiple for the purposes of tumor depletion.
Collapse
Affiliation(s)
- A G Turhan
- Translational Research-Cell Therapy Laboratory, INSERM U362, Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 1998; 16:489-96. [PMID: 9484838 DOI: 10.1038/sj.onc.1201556] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The interleukin-3 dependent murine Ba/F3 cell line has been widely used as an experimental model of cell transformation by BCR-ABL oncogenes as assessed by induction of growth-factor-independence and inhibition of apoptosis in vitro. The signaling pathways used by BCR-ABL oncogenes to exert these effects are unknown. To gain insights into this phenomenon, we have introduced the p190- and p210-encoding BCR-ABL oncogenes as well as the constitutively activated oncogenic murine erythropoietin receptor (cEpoR) into Ba/F3 and compared the behavior of individual clones in response to apoptotic stimuli. Both p210 and p190 BCR-ABL vectors induced IL-3-independent growth and the same result was obtained with the cEpo-R vector. Individual clones of Ba/F3 cells expressing BCR-ABL exhibited significant resistance to apoptosis induced by either etoposide, serum deprivation or growth-factor withdrawal. In contrast, Ba/F3 cells expressing the constitutively active cEpoR behaved like parental Ba/F3 cells undergoing apoptosis when similarly treated with etoposide or upon serum deprivation. Bc12 and Bax levels were similar in all BCR-ABL and cEpoR-transfected clones. However, in band-shift assays, nuclear extracts from growth-factor-independent Ba/F3 clones expressing cEpoR had no detectable STAT activity as opposed to the constitutive STAT activation detected in all Ba/F3 clones expressing p210 or p190 BCR-ABL. Our results indicate that although both constitutively activated cEpoR and BCR-ABL oncogenes induce growth-factor independence in Ba/F3 cells, only BCR-ABL is able to protect cells from etoposide and serum-deprivation-induced apoptosis and induce a strong constitutive activation of STAT factors, suggesting a role for these molecules in the anti-apoptotic activity of BCR-ABL.
Collapse
Affiliation(s)
- M Ahmed
- CNRS-URA 1461, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Defard M, Lemoine FM, Bonnet ML, Baillou C, Isnard F, Najman A, Guigon M. Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells. Leuk Lymphoma 1997; 27:487-94. [PMID: 9477130 DOI: 10.3109/10428199709058315] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We have compared the effects of AcSDKP, Thymosin beta4 (Tbeta4), MIP1alpha and TGFbeta on acute myeloid leukemia (AML) and B-lineage acute lymphoid leukemia (B-ALL) cells using liquid cultures in the presence of GM-CSF, IL-3 and SCF for AML cells and IL-3 and IL-7 for ALL cells. Each molecule was added daily and cell proliferation was evaluated on day 3 by thymidine incorporation. Whereas TGFbeta was found inhibitory in all the AML and B-ALL cases studied, MIP1alpha was inhibitory in 6/12 AML cases and had no effect on B-ALL cells. AcSDKP and Tbeta4 showed an inhibitory effect in a few cases but only at high doses which were inactive on normal cells. Thus, our study not only confirms the effect of TGFbeta, MIP1alpha and AcSDKP on AML cells but also provides new data concerning their effect on B-ALL and the possible inhibitory effect of AcSDKP at high doses. Furthermore, we show for the first time the effect of Tbeta4 on leukemic cells. Altogether, our data indicate differences of sensitivity of leukemic cells to negative regulators, some leukemias being inhibited by one or several of these molecules whereas others were unresponsive to all used. The clinical relevance of these observations still remains to be determined.
Collapse
Affiliation(s)
- M Defard
- Department of Hematology, Hopital St Antoine, Paris, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Canque B, Rosenzwajg M, Camus S, Yagello M, Bonnet ML, Guigon M, Gluckman JC. The effect of in vitro human immunodeficiency virus infection on dendritic-cell differentiation and function. Blood 1996; 88:4215-28. [PMID: 8943857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
CD1a+ dendritic cells (DC) differentiate from a major population of nonadherent CD13(hi)lin- cells that appear when human cord blood CD34+ hematopoietic progenitor cells are cultured with stem-cell factor, granulocyte/macrophage (MA) colony-stimulating factor, and tumor necrosis factor-alpha (TNF-alpha) for 5 days. CD13hilin- cells, which also comprise MA and granulocyte precursors, are CD4+ and can thus be targets of human immunodeficiency virus (HIV). Low replication was noted when these day 5 cells were infected with lymphotropic HIV-1LA1 (p24: < or = 4 ng/mL on day 8 postinfection [PI]), while high virus production occurred with MA-tropic HIV-1Ba-L, HIV-1Ada, or HIV-1-m-n. (p24: 50 to > or = 1,000 ng/mL). Strong cytopathicity (CPE) was then observed in nonadherent cells as in adherent MA. However, FACS analysis on day 7 PI showed that HIV did not affect differentiation of DC that survived CPE: apart from CD4 downmodulation related to HIV production, overall expression of CD40, CD80, and CD86 costimulatory molecules, and of HLA-DR, was unchanged relative to controls. At that time, the capacity of DC from HIV-infected cultures to stimulate the mixed leukocyte reaction was only altered less than 10-fold. Immunocytochemistry on day 7 PI showed that most HIV-infected cells were included in syncytia that were stained by anti-CD1a, anti-S100, and anti-CD14 antibodies, indicating that syncytia consisted of DC and cells of the MA lineage. Polymerase chain reaction analysis of FACS-sorted CD1a+ cells confirmed that they harbored then HIV DNA. Viral DNA was also detected in CD1a+ DC from noninfected cultures that had been exposed to HIV only after sorting. Therefore, we examined whether in infected cultures DC precursors were infected at the onset or if virus spread later from other infected cells to differentiated DC. This was answered by showing that, 24 hours postexposure to HIV, viral DNA was preferentially detected in day 5 sorted CD13hilin- versus CD13hilin- cells, and that it was found in the CD1a+ progeny of CD13(hi)lin- cells 48 hours later. In addition, HIV replication did not affect myeloid clonogenic progenitors in day 0 to day 7 PI cultures, although viral DNA was detected in colony-forming unit-granulocyte/macrophage (CFU-GM)/CFU-M colonies derived from day 3 and 7 PI cultures. Thus, precursors of DC and their progeny are susceptible to HIV in vitro, but, apart from CPE, the effect of virus production on DC differentiation or function is limited.
Collapse
Affiliation(s)
- B Canque
- Laboratoire de Biologie et Pathologie des Déficits Immunitaires, l'Ecole Pratique des Hautes Etudes, Faculté de Médecine, Paris, France
| | | | | | | | | | | | | |
Collapse
|
38
|
Bonnet D, Lemoine FM, Frobert Y, Bonnet ML, Baillou C, Najman A, Guigon M. Thymosin beta4, inhibitor for normal hematopoietic progenitor cells. Exp Hematol 1996; 24:776-82. [PMID: 8647227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Thymosin beta4 (Tbeta4), isolated from the calf thymus fraction 5, has a ubiquitous localization and plays a pleiotropic role in both the immune and nonimmune systems. Because it contains at its N-terminal end the sequence of a known inhibitor of hematopoiesis, the acetylated tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP, Goralatide), we have assayed Tbeta4 on human hematopoietic cells. We demonstrate that it inhibits normal bone marrow progenitor cell growth; indeed, it decreased the growth of both granulo-macrophagic and erythroid progenitors and reduces their percentage in S phase. Furthermore, we show that Tbeta4 reduces both the clonogenicity and the cell proliferation of purified CD34+ cells induced by a combination of seven growth factors. Although Tbeta4's inhibitory effect is very similar to that of AcSDKP, we demonstrate, using neutralizing antibodies and a truncated form of Tbeta4 devoid of the AcSDKP sequence, that the inhibitory effect of Tbeta4 is not mediated by the sequence AcSDKP. These data indicate that Tbeta4 is a novel inhibitor for human normal hematopoietic progenitors.
Collapse
Affiliation(s)
- D Bonnet
- Department of Hematology, CHU Saint Antoine, Paris, France
| | | | | | | | | | | | | |
Collapse
|
39
|
Turhan AG, Lemoine FM, Debert C, Bonnet ML, Baillou C, Picard F, Macintyre EA, Varet B. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 85:2154-61. [PMID: 7536493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The hierarchical level of stem cell involvement in acute promyelocytic leukemia (APL) characterized by the pathognomonic PML-RARA fusion gene is unknown. To determine if the cells of the primitive hematopoietic stem cell compartment are involved in the leukemic process, we have used molecular and cell sorting techniques in peripheral blood and bone marrow (BM) cells at diagnosis from three patients with APL and t(15; 17). In two of them, clonality analysis was also possible using the BstXI polymorphic site of the PGK gene. The PML-RARA fusion gene was readily identified by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of BM cells obtained at diagnosis in all three patients. These same samples were then used to sort CD34+ cells and their CD38+ and CD38- subsets by fluorescence-activated cell sorting. In both female patients, CD34+/CD38+ and CD34+/CD38- cell fractions were polyclonal using PCR, whereas a monoclonal pattern was identified at the BM sample obtained at diagnosis either by Southern blotting or by PCR. Because of the high sensitivity of the PCR analysis, the polyclonal pattern of these cell populations could mask the presence of a minor clone. To detect this clone, we preformed RT-PCR analysis for t(15; 17). In one female patient, the abnormal PML-RAR fusion gene was found only in the more mature CD34+/CD38+ cell fraction using a nested PCR approach, whereas the polyclonal CD34+/CD38- fraction was PML-RARA negative. These findings were confirmed in a third patient with APL in whom the PML-RARA transcripts were absent in the CD34+/CD38- cell fraction. To study the clonality at the level of clonogenic progenitors, we used in one patient PGK analysis by PCR of individual burst-forming units-erythroid and colony-forming units-granulocyte-macrophage obtained from the CD34+/CD38- and CD34+/CD38+ cell populations at diagnosis and from the BM sample obtained during remission. The two highly purified cell populations gave rise to morphologically normal colonies clonal for both the BstXI site containing (A) and the BstXI site lacking (B) PGK allelles, indicating their polyclonal content, a pattern that was also found in clonogenic progenitors obtained at remission. These findings strongly suggest that the primitive hematopoietic stem cells as defined by the CD34+/CD38- antigens are not involved by the neoplastic process in APL. These results may have important implications for autografting strategies of retinoic acid/chemotherapy-resistant or relapsed patients.
Collapse
MESH Headings
- ADP-ribosyl Cyclase
- ADP-ribosyl Cyclase 1
- Adult
- Aged
- Antigens, CD/analysis
- Antigens, CD34
- Antigens, Differentiation/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Base Sequence
- Biomarkers, Tumor/analysis
- Bone Marrow/chemistry
- Bone Marrow/pathology
- Clone Cells/chemistry
- Colony-Forming Units Assay
- Female
- Hematopoietic Stem Cells/chemistry
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/pathology
- Male
- Membrane Glycoproteins
- Middle Aged
- Molecular Sequence Data
- Neoplastic Stem Cells/chemistry
- Oncogene Proteins, Fusion/analysis
- Phosphoglycerate Kinase/genetics
- Polymerase Chain Reaction
- Polymorphism, Restriction Fragment Length
- Remission Induction
- Tumor Stem Cell Assay
Collapse
Affiliation(s)
- A G Turhan
- Service d'Hématologie Adulte, CNRS URA 1461, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
A new indirect fluorescent typing method for Klebsiella species is compared with an established method, capsular swelling. The fluorescent antibody (FA) technique was tested with standards and unknowns, and the results were checked by capsular swelling. Several unknowns were sent away for confirmation of typing, by capsular swelling. The FA method was also tried by a technician in the routine department for blind identification of standards. Fluorescence typing gives close correlation with the established capsular swelling technique but has greater sensitivity; allows more econimical use of expensive antisera; possesses greater objectivity as it requires less operator skill in the reading of results; resolves most of the cross reactions observed with capsular swelling; and has a higher per cent success rate in identification.
Collapse
|